MolecuLight i:X
Commercial- Indications
- Wound infections, Surgical site infections
Company intelligence / Profile preview
MolecuLight
Toronto, Ontario, Canadaus.moleculight.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
MolecuLight’s fluorescence imaging devices are FDA-cleared, CE-marked, and Health Canada-approved for real-time point-of-care detection of elevated bacterial burden in wounds. Clinical studies show significant improvements in wound healing rates, reduced antibiotic use and costs, faster healing times, lower risk of complications such as reinfection or osteomyelitis, and improved outcomes across all skin tones compared to standard care[2][3][4][7].
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Device
- Industry
- Medical Imaging
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on MolecuLight.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MolecuLight.